Your browser doesn't support javascript.
loading
Factors predicting survival after post-transplant hepatocellular carcinoma recurrence.
Toso, Christian; Cader, Sonia; Mentha-Dugerdil, Ariane; Meeberg, Glenda; Majno, Pietro; Morard, Isabelle; Giostra, Emiliano; Berney, Thierry; Morel, Philippe; Mentha, Gilles; Kneteman, Norman M.
Afiliação
  • Toso C; Divisions of Transplant and Abdominal Surgery, Department of Surgery, University of Geneva Hospitals, Rue Gabrielle-Perret-Gentil, 1211, Geneva, Switzerland. christian.toso@hcuge.ch
J Hepatobiliary Pancreat Sci ; 20(3): 342-7, 2013 Mar.
Article em En | MEDLINE | ID: mdl-22710887
ABSTRACT

BACKGROUND:

Although factors associated with an increased risk of recurrence after liver transplantation for hepatocellular carcinoma (HCC) have been extensively studied, the history of patients with a post-transplant recurrence is poorly known.

METHODS:

Patients experiencing a post-transplant HCC recurrence from 1996 to 2011 in two transplant programs were included. Demographic, transplant, and post-recurrence variables were assessed.

RESULTS:

Thirty patients experienced an HCC recurrence-22 men and 8 women with a mean age of 55 ± 6 years. Sixteen (53 %) were outside the Milan criteria at the time of transplantation. Most recurrences (60 %) appeared within the first 18 months after transplantation, ranging between 1.7 and 109 months (median 14.2 months). Mean post-recurrence survival was 33 ± 31 months. On univariate analysis, total tumor volume (TTV; p = 0.047), microvascular invasion (p = 0.011), and time from transplant to recurrence (p = 0.001) predicted post-recurrence survival. On multivariate analysis, both time from transplant to recurrence (p = 0.001) and history of rejection (p = 0.043), but not the location of the recurrence or the type of recurrence treatment, predicted post-recurrence survival.

CONCLUSION:

This study suggests that patients with early post-transplant HCC recurrence have worse outcomes. Those with a history of graft rejection have better survivals, possibly due to more active anti-cancer immunity.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Fígado / Carcinoma Hepatocelular / Neoplasias Hepáticas / Recidiva Local de Neoplasia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: America do norte / Europa Idioma: En Ano de publicação: 2013 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Fígado / Carcinoma Hepatocelular / Neoplasias Hepáticas / Recidiva Local de Neoplasia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: America do norte / Europa Idioma: En Ano de publicação: 2013 Tipo de documento: Article